About Voclosporin API

Mechanism of Action

Voclosporin is an immunosuppressant drug that works by inhibiting the activity of an enzyme called calcineurin. Calcineurin is involved in the activation of T cells, which are a type of white blood cell that play a key role in the immune system.

In individuals with autoimmune diseases such as lupus nephritis, the immune system mistakenly attacks healthy tissues and organs, causing inflammation and damage. Voclosporin works by blocking calcineurin and therefore inhibiting the activation of T cells, which helps to reduce the inflammation and prevent tissue damage.

In addition to its immunosuppressive effects, voclosporin has also been shown to have antiproliferative and anti-inflammatory effects, which may contribute to its ability to improve outcomes in patients with lupus nephritis.

It is important to note that while voclosporin can be effective in controlling the symptoms of autoimmune diseases, it can also suppress the immune system, making patients more susceptible to infections. As with any medication, the benefits and risks of voclosporin should be carefully weighed by a healthcare provider before it is prescribed.

Indication

Voclosporin is indicated for the treatment of certain autoimmune diseases, specifically for the treatment of lupus nephritis. Lupus nephritis is a type of kidney disease that occurs in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease in which the body's immune system attacks its own tissues and organs.

Voclosporin is used in combination with another immunosuppressant, mycophenolate mofetil, to improve kidney function and reduce the risk of kidney failure in patients with lupus nephritis.

It is important to note that the safety and effectiveness of voclosporin may vary depending on individual circumstances and that patients should consult their healthcare provider to determine if voclosporin is appropriate for their treatment. Additionally, patients taking voclosporin may require monitoring for potential side effects and drug interactions.

Dr. Reddy’sの専門知識・技術

ハイデラバード（インド）に本社を構えるDr. Reddy’s Laboratoriesは、世界的に有名な原薬（API）供給業者です。Dr. Reddy’sのAPIビジネスは米国、ヨーロッパ、ブラジル、南米、日本、中国、韓国、その他の新興市場において製薬会社の推奨パートナーとなっています。

Dr. Reddy’sのAPIビジネスは、ステロイド、ペプチド、複合長鎖分子、高薬理活性API（HPAPI /腫瘍学薬）など、複合APIの開発・製造において、30年以上にわたり高度な技術的実績を築き上げ、成長しています。この専門知識・技術は弊社の知的財産および規制関連業務の実績と共に、一貫して規制基準を満たし、それを超える優れた価値を生み出しています。Dr. Reddyの(-) API, R&D (研究開発)、IP、規制の高度な専門知識・技能の結果です。

顧客が真っ先に市場に参入するのに重要な要素は、機敏な供給網です。弊社は全施設を効率的に、そしてコストを最適化して稼働させ、品質と安全性、また、生産性の最新基準に従うことで、そうした供給網を実現させます。オフィスと工場の結びつきを強化し、ダイナミックな市場の変化に迅速に対応しています。そうした理由から、弊社は不足を解消して突発的な供給を満たすことができるのです。